Biotechnology
About
Biotechnology is part of our work in ライフサイエンス.
バイオテクノロジー分野のリーダーとして知的財産保護を手掛ける
50 年以上にわたり、弊所はバイオテクノロジーのパイオニア的企業と協力して、画期的技術の特許化、訴訟での特許権の行使、他者からの侵害や所有権の主張に対する弁護など、知的財産戦略の策定、実施に成功を収めてきました。バイオテクノロジーによって製造された最初の市販薬であるヒトインスリンに関する訴訟では、Eli Lilly and Companyの代理人として成功を収めたほか、自動 DNA シーケンシング、羊のドリーのクローニング、胎児の異数性を非侵襲的に検出する方法、プラットフォーム抗体設計など、幅広い技術に関してのカウンセリングや訴訟業務を提供してきました。
実績
Advised a biotechnology company on patents covering a well-known biologic medicine for treating eye diseases.
Advised a life sciences company in navigating the patent landscape in the DNA sequencing space and preparing to clear the way for its human genomic sequencing technology.
Advised a global pharma company on loss of exclusivity and enforcement strategy in relation to its platelet inhibitor drug.
Finnegan represents BrainCo, a developer of brain-machine interface (BMI) wearables that combine electroencephalography (EEG) signal processing with artificial intelligence (AI) and machine learning (ML) to enable users to control electronic devices using brain signals. The firm works with BrainCo to develop and implement its intellectual property strategy, including drafting and prosecuting utility and design patent applications, in support of the company’s efforts to build a robust patent portfolio covering innovations and designs related to BMI technologies used in toys, smart home appliances, and robotic devices.
Representing Sarepta in defensive patent litigation involving Elevidys®, a one-time gene therapy for the treatment of a neuromuscular disease known as Duchenne muscular dystrophy (DMD) and in parallel offensive inter partes reviews (IPRs).
1:24-cv-00882, D. Del., Judge Andrews
2:23-cv-00094, 2:23-cv-02364, D.N.J., Judges Cecchi, Padin, Wettre
